First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
収録刊行物
-
- Annals of Oncology
-
Annals of Oncology 26 (9), 1883-1889, 2015-09
Elsevier BV